- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib ; day:15 ; month:6 ; year:2024 ; pages:1-5
Leukemia ; (15.6.2024), 1-5
- Creator
-
Leske, Inga B.
Hantschel, Oliver
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-024-02314-7
- URN
-
urn:nbn:de:101:1-2408220855502.134391682291
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Leske, Inga B.
- Hantschel, Oliver
- SpringerLink (Online service)
Other Objects (12)
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia
Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Genomische BCR-ABL1-Bruchpunkte bei kindlichen Leukämien
Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms
Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Decrypting the role of HSP90α and β isoforms in BCR-ABL1+ leukemia and Characterization of Small Molecule HSP90 Inhibitors and Degraders
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K
The role of proteostasis in BCR-ABL1-positive acute lymphoblastic leukemia